Orgenesis has entered into a definitive securities purchase agreement with certain accredited investors for the sale of 2,272,719 shares of the Company’s common stock, warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $2.00 per share in a private placement at a purchase price of $1.03 per share and associated warrants. The warrants are exercisable immediately and expire five years from the date of issuance. The Company expects to receive gross proceeds of approximately $2.3 million before deducting related offering expenses. The offering is expected to close on or about March 5, 2024, subject to customary closing conditions. The financing includes among others participation from healthcare industry executives and physicians.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORGS:
- Orgenesis Inc. Announces $2.3 Million Private Placement
- Orgenesis awarded EUR 2M grant from Walloon Government in Belgium
- Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
- Orgenesis Inc Strikes Definitive Deal to Acquire Octomera LLC
- Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic